Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: Oncology

Amgen Pauses or Discontinues Several Therapeutics in Oncology Pipeline

Amgen released its financial results for the fourth quarter and full year 2020. Among the key results, Amgen disclosed that […]

Amgen Pauses or Discontinues Several Therapeutics in Oncology Pipeline
4 weeks ago
Share

Amgen Announces Positive Interim Data from CodeBreaK 100 Trial of Sotorasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

Amgen announced results from the Phase 2 cohort of the CodeBreaK 100 study evaluating sotorasib (AMG 510) in 126 patients […]

Amgen Announces Positive Interim Data from CodeBreaK 100 Trial of Sotorasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
4 weeks ago
Share

Dr. Ian Smith And Stuart Young Talk About Lessons From Covid-19: Strategy For Recruiting Patients

  An Interview with Dr. Ian Smith, Founder, Director and Chief Medical Officer of Panthera Biopartners and CEO of Panthera […]

1 month ago
Share

NIH Awards $4m for Memorial Sloan Kettering & City College NY to Train AI to Detect Breast Cancer Tumors in At-Risk Women

The National Institutes of Health awarded $4 million to Memorial Sloan Kettering Cancer Center (MSKCC) and the City College of […]

NIH Awards $4m for Memorial Sloan Kettering & City College NY to Train AI to Detect Breast Cancer Tumors in At-Risk Women
1 month ago
Share

FDA Grants Orphan Drug Designation to BCMA-targeting Specific T Cell Activating Recombinant Protein (HPN217) for Patients with Multiple Myeloma

The U.S. Food and Drug Administration decided to open the Orphan Drug Designation (ODD) to an investigational drug for the […]

FDA Grants Orphan Drug Designation to BCMA-targeting Specific T Cell Activating Recombinant Protein (HPN217) for Patients with Multiple Myeloma
1 month ago
Share

Regional Oncology Network Joins OneOncology Platform and the ‘OneR’ Clinical Trials Network

A group of 37 medical and radiation oncologists, along with a robust staff of cancer care providers, led by Drs. […]

Regional Oncology Network Joins OneOncology Platform and the ‘OneR’ Clinical Trials Network
1 month ago
Share

China’s Regulator Accepts Amgen’s Sotorasib for Breakthrough Therapy Designation as a First Milestone

Amgen, a leading global biotech company based in Southern California reported a first—the first time it has successfully achieved Breakthrough […]

China’s Regulator Accepts Amgen’s Sotorasib for Breakthrough Therapy Designation as a First Milestone
1 month ago
Share

St. Baldrick’s Foundation and TeamConnor Childhood Cancer Foundation Partner to Back the Work of Dr. Erica Braverman at Children’s Hospital of Pittsburgh

A prominent non-government funder of childhood research grants, the St. Baldrick’s Foundation, formalized a partnership with the Dallas, Texas, based […]

St. Baldrick’s Foundation and TeamConnor Childhood Cancer Foundation Partner to Back the Work of Dr. Erica Braverman at Children’s Hospital of Pittsburgh
1 month ago
Share

AstraZeneca’s Calquence Meets Primary Efficacy Endpoint in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia

AstraZeneca reported positive results from the phase 3 ELEVATE-RR trial, which evaluated AstraZeneca’s Calquence (acalabrutinib) versus ibrutinib in adults with previously treated, […]

AstraZeneca’s Calquence Meets Primary Efficacy Endpoint in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia
1 month ago
Share

BeiGene’s Tislelizumab Meets Endpoints in Phase 3 Trial for Esophageal Cancer

BeiGene reported positive results from the global Phase RATIONALE 302 trial evaluating its anti-PD-1 antibody tislelizumab versus investigator’s choice chemotherapy […]

BeiGene’s Tislelizumab Meets Endpoints in Phase 3 Trial for Esophageal Cancer
1 month ago
Share

Posts navigation

Older posts
Newer posts

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.